Literature DB >> 22677432

Algorithm for codevelopment of new drug-predictive biomarker combinations: accounting for inter- and intrapatient tumor heterogeneity.

David R Gandara1, Tianhong Li, Primo N Lara, Philip C Mack, Karen Kelly, Suzanne Miyamoto, Neal Goodwin, Laurel Beckett, Mary W Redman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22677432      PMCID： PMC4049356          DOI： 10.1016/j.cllc.2012.05.004

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN： 1525-7304            Impact factor:   4.785


× No keyword cloud information.
  19 in total

Review 1.  Targeted therapy: wave of the future.

Authors:  Mark D Pegram; Richard Pietras; Alex Bajamonde; Pamela Klein; Gwen Fyfe
Journal:  J Clin Oncol       Date:  2005-03-10       Impact factor: 44.544

Review 2.  Clinical trial designs for predictive marker validation in cancer treatment trials.

Authors:  Daniel J Sargent; Barbara A Conley; Carmen Allegra; Laurence Collette
Journal:  J Clin Oncol       Date:  2005-03-20       Impact factor: 44.544

3.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

4.  Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

Authors:  Robert C Doebele; Amanda B Pilling; Dara L Aisner; Tatiana G Kutateladze; Anh T Le; Andrew J Weickhardt; Kimi L Kondo; Derek J Linderman; Lynn E Heasley; Wilbur A Franklin; Marileila Varella-Garcia; D Ross Camidge
Journal:  Clin Cancer Res       Date:  2012-01-10       Impact factor: 12.531

5.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Authors:  Thomas J Lynch; Daphne W Bell; Raffaella Sordella; Sarada Gurubhagavatula; Ross A Okimoto; Brian W Brannigan; Patricia L Harris; Sara M Haserlat; Jeffrey G Supko; Frank G Haluska; David N Louis; David C Christiani; Jeff Settleman; Daniel A Haber
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

6.  Randomized phase III clinical trial designs for targeted agents.

Authors:  Antje Hoering; Mike Leblanc; John J Crowley
Journal:  Clin Cancer Res       Date:  2008-07-15       Impact factor: 12.531

7.  MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Authors:  Jeffrey A Engelman; Kreshnik Zejnullahu; Tetsuya Mitsudomi; Youngchul Song; Courtney Hyland; Joon Oh Park; Neal Lindeman; Christopher-Michael Gale; Xiaojun Zhao; James Christensen; Takayuki Kosaka; Alison J Holmes; Andrew M Rogers; Federico Cappuzzo; Tony Mok; Charles Lee; Bruce E Johnson; Lewis C Cantley; Pasi A Jänne
Journal:  Science       Date:  2007-04-26       Impact factor: 47.728

8.  Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Authors:  Manabu Soda; Young Lim Choi; Munehiro Enomoto; Shuji Takada; Yoshihiro Yamashita; Shunpei Ishikawa; Shin-ichiro Fujiwara; Hideki Watanabe; Kentaro Kurashina; Hisashi Hatanaka; Masashi Bando; Shoji Ohno; Yuichi Ishikawa; Hiroyuki Aburatani; Toshiro Niki; Yasunori Sohara; Yukihiko Sugiyama; Hiroyuki Mano
Journal:  Nature       Date:  2007-07-11       Impact factor: 49.962

9.  Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study.

Authors:  Kerby Shedden; Jeremy M G Taylor; Steven A Enkemann; Ming-Sound Tsao; Timothy J Yeatman; William L Gerald; Steven Eschrich; Igor Jurisica; Thomas J Giordano; David E Misek; Andrew C Chang; Chang Qi Zhu; Daniel Strumpf; Samir Hanash; Frances A Shepherd; Keyue Ding; Lesley Seymour; Katsuhiko Naoki; Nathan Pennell; Barbara Weir; Roel Verhaak; Christine Ladd-Acosta; Todd Golub; Michael Gruidl; Anupama Sharma; Janos Szoke; Maureen Zakowski; Valerie Rusch; Mark Kris; Agnes Viale; Noriko Motoi; William Travis; Barbara Conley; Venkatraman E Seshan; Matthew Meyerson; Rork Kuick; Kevin K Dobbin; Tracy Lively; James W Jacobson; David G Beer
Journal:  Nat Med       Date:  2008-07-20       Impact factor: 53.440

10.  Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

Authors:  Robert Pirker; Jose R Pereira; Aleksandra Szczesna; Joachim von Pawel; Maciej Krzakowski; Rodryg Ramlau; Ihor Vynnychenko; Keunchil Park; Chih-Teng Yu; Valentyn Ganul; Jae-Kyung Roh; Emilio Bajetta; Kenneth O'Byrne; Filippo de Marinis; Wilfried Eberhardt; Thomas Goddemeier; Michael Emig; Ulrich Gatzemeier
Journal:  Lancet       Date:  2009-05-02       Impact factor: 79.321
View more
  12 in total

1.  Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implications.

Authors:  David R Gandara; Tianhong Li; Primo N Lara; Karen Kelly; Jonathan W Riess; Mary W Redman; Philip C Mack
Journal:  Clin Lung Cancer       Date:  2013-10-12       Impact factor: 4.785

Review 2.  Human cancer growth and therapy in immunodeficient mouse models.

Authors:  Leonard D Shultz; Neal Goodwin; Fumihiko Ishikawa; Vishnu Hosur; Bonnie L Lyons; Dale L Greiner
Journal:  Cold Spring Harb Protoc       Date:  2014-07-01

3.  Bridging tumor genomics to patient outcomes through an integrated patient-derived xenograft platform.

Authors:  David R Gandara; Philip C Mack; Carol Bult; Tianhong Li; Primo N Lara; Jonathan W Riess; Stephanie H Astrow; Regina Gandour-Edwards; David T Cooke; Ken Y Yoneda; Elizabeth H Moore; Chong-Xian Pan; Rebekah A Burich; Elizabeth A David; James G Keck; Susan Airhart; Neal Goodwin; Ralph W de Vere White; Edison T Liu
Journal:  Clin Lung Cancer       Date:  2015-03-18       Impact factor: 4.785

4.  Influence of chemotherapy on EGFR mutation status.

Authors:  Yung-Hung Luo; Yuh-Min Chen
Journal:  Transl Lung Cancer Res       Date:  2013-12

Review 5.  Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies.

Authors:  Tianhong Li; Hsing-Jien Kung; Philip C Mack; David R Gandara
Journal:  J Clin Oncol       Date:  2013-02-11       Impact factor: 44.544

6.  Profiling cancer gene mutations in clinical formalin-fixed, paraffin-embedded colorectal tumor specimens using targeted next-generation sequencing.

Authors:  Liangxuan Zhang; Liangjing Chen; Sachin Sah; Gary J Latham; Rajesh Patel; Qinghua Song; Hartmut Koeppen; Rachel Tam; Erica Schleifman; Haider Mashhedi; Sreedevi Chalasani; Ling Fu; Teiko Sumiyoshi; Rajiv Raja; William Forrest; Garret M Hampton; Mark R Lackner; Priti Hegde; Shidong Jia
Journal:  Oncologist       Date:  2014-03-24

Review 7.  Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS.

Authors:  Grzegorz J Korpanty; Donna M Graham; Mark D Vincent; Natasha B Leighl
Journal:  Front Oncol       Date:  2014-08-11       Impact factor: 6.244

8.  Higher susceptibility of NOD/LtSz-scid Il2rg (-/-) NSG mice to xenotransplanted lung cancer cell lines.

Authors:  Nobuhiro Kanaji; Akira Tadokoro; Kentaro Susaki; Saki Yokokura; Kiyomi Ohmichi; Reiji Haba; Naoki Watanabe; Shuji Bandoh; Tomoya Ishii; Hiroaki Dobashi; Takuya Matsunaga
Journal:  Cancer Manag Res       Date:  2014-10-21       Impact factor: 3.989

Review 9.  Current and Prospective Protein Biomarkers of Lung Cancer.

Authors:  Tatiana N Zamay; Galina S Zamay; Olga S Kolovskaya; Ruslan A Zukov; Marina M Petrova; Ana Gargaun; Maxim V Berezovski; Anna S Kichkailo
Journal:  Cancers (Basel)       Date:  2017-11-13       Impact factor: 6.639

10.  Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression.

Authors:  Andrés Felipe Cardona; Leonardo Rojas; Beatriz Wills; Oscar Arrieta; Hernán Carranza; Carlos Vargas; Jorge Otero; Mauricio Cuello; Luis Corrales; Claudio Martín; Carlos Ortiz; Sandra Franco; Rafael Rosell
Journal:  PLoS One       Date:  2016-05-18       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.